RCA
IMNN icon

Riverview Capital Advisers’s Imunon IMNN Stock Holding History

Riverview Capital Advisers’s Portfolio IMNN Stock Details IMNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Hold
34,364
– – 0.08% 74
2025
Q4 		$248K Hold
34,364
– – 0.08% 80
2025
Q3 		$248K Buy
34,364
+33,466
+3,727% +$224K 0.07% 85
2025
Q2 		$9.37K Buy
+898
New +$12.3K ﹤0.01% 95

Other funds holding IMNN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Riverview Capital Advisers's IMNN Position: Q1 2026 in Review

Riverview Capital Advisers held its Imunon (IMNN) position steady in Q1 2026 at 34,364 shares worth $248K. The position accounts for 0.08% of the portfolio, ranked #74.

Riverview Capital Advisers first reported a position in IMNN in Q2 2025 and has held it in 4 quarters since. 19 funds tracked by Wall St. Rank hold IMNN as of Q1 2026.

  • Riverview Capital Advisers held 34,364 shares of Imunon worth $248K as of Q1 2026.
  • Riverview Capital Advisers left its Imunon share count unchanged in Q1 2026.
  • Imunon made up 0.08% of Riverview Capital Advisers's portfolio in Q1 2026, its #74 holding.
  • Riverview Capital Advisers first reported a position in Imunon in Q2 2025 and has held it in 4 quarters since.
  • 19 funds tracked by Wall St. Rank held Imunon as of Q1 2026.

Based on Riverview Capital Advisers's 13F filing for Q1 2026, filed 14 May 2026.